scispace - formally typeset
M

Mahmoud Benltifa

Researcher at Claude Bernard University Lyon 1

Publications -  8
Citations -  303

Mahmoud Benltifa is an academic researcher from Claude Bernard University Lyon 1. The author has contributed to research in topics: Glycogen phosphorylase & Chemistry. The author has an hindex of 5, co-authored 6 publications receiving 284 citations. Previous affiliations of Mahmoud Benltifa include University of Lyon & Centre national de la recherche scientifique.

Papers
More filters
Journal ArticleDOI

1,3-Dipolar cycloaddition reactions on carbohydrate-based templates: synthesis of spiro-isoxazolines and 1,2,4-oxadiazoles as glycogen phosphorylase inhibitors

TL;DR: In this paper, a 1,3-Dipolar cycloaddition of aryl nitrile oxides to benzyl/acetyl-protected exo -glucals and to a benzoylated glucosyl cyanide led in high yield to spiro-isoxazolines and to 3-aryl-5-glucosyl-1,2,4-oxadiazoles, respectively.
Journal ArticleDOI

Synthesis and structure-activity relationships of C-glycosylated oxadiazoles as inhibitors of glycogen phosphorylase

TL;DR: The 5-beta-D-glucopyranosyl-3-(4-methylphenyl- and -2-naphthyl)-1,2,4-oxadiazoles were practically inefficient as inhibitors of rabbit muscle glycogen phosphorylase b while the 2,6-anhydro-aldose benzoylhydrazones displayed inhibitory activities in the micromolar range.
Journal ArticleDOI

Glucose-based spiro-isoxazolines: a new family of potent glycogen phosphorylase inhibitors.

TL;DR: Docking calculations with GLIDE in extra-precision (XP) mode yielded excellent agreement with experiment, as judged by comparison of the predicted binding modes of the five ligands with the crystallographic conformations and the good correlation between the docking scores and the experimental free binding energies.
Journal ArticleDOI

Glucose-based spiro-heterocycles as potent inhibitors of glycogen phosphorylase

TL;DR: The 2-naphthyl-substituted 1,4,2-oxathiazole displayed the best inhibition against RMGPb (K(i)=160 nM), among glucose-based inhibitors known to date, among glucopyranosylidene-spiro-1,2,4-oxadiazolines.